NASDAQ$CDXS

Codexis Inc · Q4 2021 earnings

Q4 2021 earnings · · Investor relations

Briefing

Codexis reported an increase in fourth quarter revenue and provided 2022 revenue guidance.

Codexis announced financial results for Q4 and fiscal year ended December 31, 2021. The company's total revenues for the fourth quarter 2021 were $24.5 million, an increase of 16% from $21.0 million in the fourth quarter 2020.

  • Total revenues for the fourth quarter 2021 were $24.5 million, an increase of 16% from $21.0 million in the fourth quarter 2020.
  • Product revenues for the fourth quarter 2021 were $17.0 million compared to $12.2 million in fourth quarter 2020, driven by higher enzyme sales to Pfizer.
  • Product gross margin for the fourth quarter 2021 was 59.9% compared to 52.0% in the fourth quarter 2020, driven by increased sales of higher margin products.
  • The net loss for the fourth quarter 2021 was $10.2 million, or $0.16 per share, compared to $3.9 million, or $0.06 per share, for the fourth quarter 2020.

Headline financials

Total Revenue

$24.5M

Previous: $21M+16.5%
EPS (adj)

-$0.16

Previous: -$0.06-166.7%
Capital Expenditures

$5.48M

Previous: $1.49M+268.3%
Free Cash Flow

-$4.82M

Previous: -$2.98M-61.7%
Net Income

-$10.2M

Previous: -$3.92M-159.9%
Operating Income

-$10.4M

Previous: -$3.92M-164.8%
Gross Profit

$10.2M

Previous: $6.36M+60.1%
Cash & Equivalents

$117M

Previous: $149M-21.7%
Total Assets

$246M

Previous: $222M+11.2%
Stock-Based Comp

$3.05M

Previous: $1.64M+86.2%

Revenue & EPS history

Codexis · Revenue · Quarterly

$24.5M

Q4 2021+16.5%vs Q4 2020
Beat estimate in 7 of 16 quarters(44%)
ActualEstimate

Forward guidance

Codexis is introducing financial guidance for 2022. Total revenues are expected to be in the range of $152 million to $158 million. Product revenues are expected to be in the range of $112 million to $118 million. Gross margin on product revenue is expected to be 65% to 70%.

Tailwinds

  • Total revenues are expected to be in the range of $152 million to $158 million, an increase of nearly 50% at the midpoint compared to 2021.

Headwinds

  • excluding revenue from Pfizer in both periods, revenue growth is projected to be 10% or more.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2021

Historical avgQ4 2021

-0.4%

Avg return

Earnings day

-0.0%

Avg return

5 days after

+1.2%

Avg return

30 days after

48%

31 / 64 earnings

Positive

+33.9%

Q4 2025

Best reaction

-24.5%

Q2 2012

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-3.0%-4.5%-4.5%
Q4 2025+33.9%+15.7%+76.4%
Q3 2025-4.3%-8.9%-26.7%
Q1 2025+1.2%-0.8%-9.7%
Q4 2024-22.6%-30.5%-28.5%
Q3 2024+9.0%+19.0%+42.7%
Q2 2024-7.3%-7.3%-9.3%
Q1 2024+26.0%+13.5%+8.7%
Q4 2023+12.0%+1.4%-15.9%
Q3 2023+16.3%+4.8%+48.8%
Q2 2023-10.0%-28.7%-43.9%
Q1 2023-8.1%-24.4%-35.7%
Q4 2022-14.0%-12.0%-29.5%
Q3 2022+10.3%+4.9%-1.4%
Q2 2022+12.5%+0.0%-13.4%
Q1 2022-9.2%-17.3%-20.9%
Q4 2021+15.9%+13.5%+13.1%
Q3 2021+18.8%+18.7%-3.7%
Q2 2021+17.2%+18.6%+29.2%
Q1 2021-5.0%-9.9%-0.4%
Q4 2020-3.4%-1.3%-9.6%
Q3 2020+2.3%+9.1%+23.9%
Q2 2020+6.8%+1.9%-4.9%
Q1 2020+2.3%-2.9%+2.2%
Q4 2019-10.2%-12.2%-20.6%
Q3 2019+10.1%+11.4%+10.0%
Q2 2019-14.4%-14.9%-15.9%
Q1 2019-5.7%-3.3%-11.9%
Q4 2018-1.6%-5.3%-7.7%
Q3 2018-7.2%-9.0%+25.3%
Q2 2018+4.0%+10.4%+32.0%
Q1 2018+9.1%+14.2%+25.9%
Q4 2017+3.3%+18.6%-3.3%
Q3 2017-3.1%-8.5%+6.2%
Q2 2017+5.9%+5.0%+10.9%
Q1 2017+1.1%+0.0%-2.2%
Q4 2016+6.0%+8.3%+7.1%
Q3 2016+2.2%+10.8%+8.6%
Q2 2016+2.8%+0.0%-4.2%
Q1 2016+2.5%
Q4 2015-5.9%
Q3 2015+2.9%
Q2 2015-3.1%
Q1 2015-7.4%
Q4 2014+5.4%
Q3 2014-8.1%
Q2 2014+7.1%
Q1 2014+1.3%
Q4 2013+3.1%
Q3 2013-16.6%
Q2 2013-12.5%
Q1 2013+0.5%
Q4 2012-8.5%
Q3 2012-17.4%
Q2 2012-24.5%
Q1 2012-2.4%
Q4 2011-8.7%
Q3 2011+0.4%
Q2 2011-9.3%
Q1 2011-5.6%
Q4 2010-1.5%
Q3 2010-8.1%
Q2 2010-5.5%
Q1 2010-0.7%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro